Compare SMWB & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | PROF |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.5M | 243.2M |
| IPO Year | 2021 | 2017 |
| Metric | SMWB | PROF |
|---|---|---|
| Price | $3.06 | $7.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 740.2K | 79.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $11.07 | $92.40 |
| Revenue Next Year | $11.17 | $64.10 |
| P/E Ratio | ★ N/A | $37.95 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.22 | $3.92 |
| 52 Week High | $10.75 | $8.95 |
| Indicator | SMWB | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 55.36 |
| Support Level | $2.40 | $7.00 |
| Resistance Level | $7.82 | $7.94 |
| Average True Range (ATR) | 0.27 | 0.41 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 44.57 | 44.61 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.